Clinical and in vitro response to 13-cis-retinoic acid in interferon- alpha resistant renal cell carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 3, 1997, Pages 143-147

  Buer, Jan ^a   Probst, Michael ^a   Duensing, Stefan ^a   Köditz, Harald ^a   Franzke, Anke ^a   Dallmann, Iris ^a   Ganser, Arnold ^a   Atzpodien, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; VINBLASTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030751652     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.143     Document Type: Article

References (12)

1. Wingo PA, Tong T, and Bolden S. Cancer statistics. CA Cancer J Clin 1995;45.8-30.
2. Linehan M, Shipley WU, and Parkinson DR. Cancer of the kidney and ureter. In: De Vita VT Jr, Hellmann S, and Rosenberg SA, editors. Cancer: principles and practices of oncology. Vol 2, 4th ed., Philadelphia, Lippincott, 1993:1023-1051.
3. Rodriguez-Villanueva J, and McDonnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-α. Int J Cancer 1995;61:110-114.
4. Warrell RP. Applications for retinoids in cancer therapy Sem Hematol 1994;31(suppl):1-13.
5. Toma S, Monteghirfo S, Tasso P, Nicolo G, Spadini N, Palumbo R, and Molina F. Antiproliferative and synergistic effect of interferon alpha-2, retinoids and their association in established human cancer cell lines. Cancer Lett 1994;82:209-216.
6. Buer J, Probst M, Ganser A, and Atzpodien J. Response to 13-cis-retinoic acid plus interferon alpha2a in two patients with therapy-refractory advanced renal cell carcinoma. J Clin Oncol 1995;13:2679-2680.
7. Motzer RJ, Schwartz L, Murray-Law T, Murphy BA, Hoffman AD, Albino AP, Vlamis V, and Nanus DM. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-1957
8. Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh J, Hong WK, Borden EC, Paredes-Espinoza M, and Krakoff IW. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Sem Hematol 1994;31(suppl):31-37.
9. Eckhardt S. Diagnosis, staging and principles of management In: Hossfeld DK, Sherman CD, Love FX, and Bosch FX, editors. Manual of clinical oncology. 5th ed., Berlin, Springer 1990:90-107.
10. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, and Krown SE Interferon-alpha2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1991;11:1368-1375.
11. Chandler D, El-Naggar AK, Brisbay S, Redline RW, and McDonnell TJ. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis Hum Pathol 1994;25:789-796.
12. Lancilotti F, Giandomenico V, Affabris E, Fiorucci G, Romeo G, and Rossi GB. Interferon α-2a and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 1995,55:3158-3164